ArticleTherapeutic advances in gastroenterology2025

Cost-effectiveness analysis of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy for advanced HER2-negative gastric or gastro-esophageal junction cancer.

Yitian Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.